Another preclinical study by Yang et al. reported the development of a novel HER2-targeting CAR-T cell that incorporated a CD28 costimulatory domain and a PD-1 blocking domain to enhance its function and persistence against HER2-positive gastric cancer cells (18). This evidence concerns the gene ERBB2 and gastric cancer.